Inflammation in end-stage renal disease: Sources, consequences, and therapy

Seminars in Dialysis

Volumn 15, Issue 5, 2002, Pages 329-337

  Stenvinkel, Peter ^a   Alvestrand, Anders ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; COMORBIDITY; FEMALE; HUMAN; INFLAMMATION; MALE; METABOLISM; METHODOLOGY; PREDICTION AND FORECASTING; PROBABILITY; PROGNOSIS; RENAL REPLACEMENT THERAPY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURVIVAL;

CARDIOVASCULAR DISEASES; COMORBIDITY; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; KIDNEY FAILURE, CHRONIC; MALE; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROGNOSIS; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 0036719916     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1046/j.1525-139X.2002.00083.x     Document Type: Review

References (110)

1. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis 32(suppl 5):S112-S119, 1998
2. Lindner A, Charra B, Sherrard DJ, Schribner BH: Accelerated atherosclerosis in prolonged maintenance haemodialysis. N Engl J Med 290:697-701, 1974
3. Ishimura E, Shoji T, Emoto M, Motoyama K, Shinohara K, Matsumoto N, Taniwaki H, Inaba M, Nishizawa Y: Renal insufficiency accelerates atherosclerosis in patients with type 2 diabetes mellitus. Am J Kidney Dis 38(suppl 1):S186-S190, 2001
4. Parfrey PS: Is renal insufficiency an atherogenic state? Reflections on prevalence, incidence and risk. Am J Kidney Dis 37:154-156, 2001
5. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, Levey AS: Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 58:353-362, 2000
6. Zoccali C, Bode-Böger SM, Mallamaci F, Bendetto FA, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich JC, Boger RH: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358:2113-2117, 2001
7. Stenvinkel P: Inflammatory and atherosclerotic interactions in the depleted uremic patient. Blood Purif 19:53-61, 2001
8. Samak MJ, Levey AS: Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 35:S117-S131, 2000
9. Stenvinkel P: Endothelial dysfunction and inflammation-is there a link? Nephrol Dial Transplant 16:1968-1971, 2001
10. Stenvinkel P: Inflammation in end-stage renal failure: could it be treated? Nephrol Dial Transplant 17[Supp 8]: 33-38, 2002
11. Ayus JC, Sheikh-Hamad D: Silent infection in clotted hemodialysis access grafts. J Am Soc Nephrol 9:1314-1321, 1998
12. Heinrich J, Schulte H, Schönfeld R, Köhler E, Assmann G: Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost 73:374-378, 1995
13. Stenvinkel P, Heimbürger O, Jogestrand O, Kärnell A, Samuelsson A: Does persistent infection with Chlamydia pneumoniae increase the risk of atherosclerosis in chronic renal failure? Kidney Int 55:2531-2532, 1999
14. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Fermo I, Focá A, Paroni R, Malatino LS: Inflammation is associated with carotid atherosclerosis in dialysis patients. J Hypertens 18:1207-1213, 2000
15. Spittle M, Craig R, Adhikarla R, Ronco C, Lewin NW: Relationship between antibodies to periodontal pathogens and C-reactive protein (CRP) levels in hemodialysis patients. J Am Soc Nephrol 11:299A, 2000
16. Nakanishi I, Moutabarrik A, Okada N, Kitamura E, Hayashi A, Syouji T, Namiki M, Ishibashi M, Zaid D, Tsubakihara Y: Interleukin-8 in chronic renal failure and dialysis patients. Nephrol Dial Transplant 9:1435-1442, 1994
17. Brockhaus M, Bar-Khayim Y, Gurwicz S, Frensdorff A, Haran N: Plasma tumour necrosis factor soluble receptors in chronic renal failure. Kidney Int 42:663-667, 1992
18. Descamps-Latscha B, Herbelin A, Nguyen AT, Roux-Lombard P, Zingraf T J, Moynot A, Verger C, Dahmane D, de Groote D, Junger P, Dayer JM: Balance between IL-1β, TNF-α, and their specific inhibitors in chronic renal failure and maintenance dialysis. J Immunol 154:882-892, 1995
19. van Riemsdijk-van Overbeeke IC, Baan CC, Hesse CJ, Loonen EHM, Niesters HGM, Zietse R, Weimar W: TNF-α:mRNA, plasma protein levels and soluble receptors in patients with chronic hemodialysis, on CAPD and with end-stage renal failure. Clin Nephrol 53:115-123, 2000
20. Memoli B, Postiglione L, Cianciaruso B, Bisesti V, Cimmaruta C, Marzano L, Minutolo R, Cuomo V, Guida B, Andreuicci M, Rossi G: Role of different dialysis membranes in the release of interleukin-6 soluble receptor in uremic patients. Kidney Int 58:417-424, 2000
21. Bolton CH, Downs LG, Victory JGG, Dwight JF, Tomson CRV, Mackness MI, Pinkney JH: Endothelial dysfunction in chronic renal failure, roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant 16:1189-1197, 2001
22. Chung SH, Heimburger O, Stenvinkel P, Bergstrom J, Lindholm B: Association between inflammation and changes in residual renal function and peritoneal transport rate during the first year of dialysis. Nephrol Dial Transplant 16:2240-2245, 2001
23. Bemelmans MH, Gouma DJ, Buurman WA: Influence of nephrectomy on tumor necrosis factorclearance in murine model. J Immunol 150:2007-2017, 1993
24. Poole S, Bird TA, Selkirk S, Gaines-Das RE, Choudry Y, Stephenson SL, Kenny AJ, Saklatvaa J: Fate of injected interleukin 1 in rats: sequestration and degradation in the kidney. Cytokine 2:416-422, 1990
25. Espinoza M, Aguilera A, Auxiliarda BM, Codoceo R, Caravaca E, Cirugeda A, del Peso G, Hevia C, Selgas R: Tumour necrosis factor alpha as uremic toxin: correlation with neuropathy, left ventricular hypertrophy, anemia, and hypertrialyceridemia in peritoneal dialysis patients. Adv Perit Dial 15:82-86, 1999
26. Vanholder R, Argilés A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Massy ZA, Rodriguez M, Stegmayr B, Stenvinkel P, Wratten M: Uremic toxicity: present state of the art. Int J Artif Organs 24:695-725, 2001
27. Cavaillon JM, Poignet JL, Fitting C, Delons S: Serum interleukin-6 in long-term hemodialysed patients. Nephron 60:307-313, 1992
28. Libetta C, De Nicola L, Rampino T, De Simone W, Memoli B: Inflammatory effects of peritoneal dialysis: evidence of systemic monocyte activation. Kidney Int 49:506-511, 1996
29. Schouten WEM, Grooteman MPC, van Houte A-J, Schoorl M, van Limbeek J, Nubé MJ: Effects of dialyser and dialysate on the acute phase response in clinical bicarbonate dialysis. Nephrol Dial Transplant 15:379-384, 2000
30. Tielemans C, Husson C, Schurmans T, Gastaldello K, Madhoun P, Delville JP, Marchant A, Goldman M, Vanherweghem JL: Effects of ultrapure and non-sterile dialysate on the inflammatory response during in vitro hemodialysis. Kidney Int 49:236-243, 1996
31. Panichi V, Migliori M, De Pietro S, Taccola D, Metelli MR, Perez R, Palla R, Rindi P, Cristofani R, Tetta C: Plasma C-reactive protein in hemodialysis patients: a cross-sectional and longitudinal survey. Blood Purif 18:30-36, 2000
32. Kaysen GA, Dublin JA, Müller HG, Rosales LM, Levin NW: The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients. Kidney Int 58:346-352, 2000
33. Stenvinkel P, Heimbürger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation and atherosclerosis in chronic renal failure. Kidney Int 55:1899-1911, 1999
34. Panichi V, Migliori M, De Pietro S, Taccola D, Bianchi AM, Norpoth M, Metelli MR, Giovanni L, Tetta C, Palla R: C-reactive protein in patients with chronic renal diseases. Renal Failure 23:551-562, 2001
35. Kaysen G, Chertow GM, Adhikarla R, Young B, Ronco C, Levin NW: Inflammation and dietary protein intake exert competing effects on serum albumin and creatinine in hemodialysis patients. Kidney Int 60:333-340, 2001
36. Lowrie EG, Lew NL: Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15:458-482, 1990
37. Avram MM, Fein PA, Bonomini L, Mittman N, Loutoby R, Avram DK, Chattopadhyay J: Predictors of survival in continuous ambulatory peritoneal dialysis patients: a five year prospective study. Perit Dial Int 16(suppl 1):S190-S194, 1996
38. Qureshi AR, Alvestrand A, Divinho-Filho JC, Gutierrez A, Heimbürger O, Lindholm B, Bergstrom J: Inflammation, malnutrition and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol 13(suppl 1):S28-S36, 2002
39. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55:648-658, 1999
40. Yeun JY, Levine RA, Mantadilok V, Kaysen GA: C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 35:469-476, 2000
41. Noh H, Lee SW, Kang SW, Shin SK, Choi KH, Lee HY, Han DS: Serum C-reactive protein: a predictor of mortality in continuous ambulatory peritoneal dialysis patients. Nephrol Dial Transplant 18:387-394, 1998
42. Stenvinkel P, Heimburger O, Wang T, Lindholm B, Bergstrom J, Elinder CG: High serum hyaluronan indicates poor survival in renal replacement therapy. Am J Kidney Dis 34:1033-1088, 1999
43. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH: Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101:1767-1772, 2000
44. Ridker PM, Cushman M, Stampfer MJ, Russell PT, Hennekens CH: Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973-979, 1997
45. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen M, D'Agostino RB, Kuller LM: Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with Framingham study. Am J Epidemiol 145:408-415, 1997
46. Mutru O, Laakso M, Isomaki H, Koota K: Cardiovascular mortality in patients with rheumatoid arthritis. Cardiology 76:71-77, 1989
47. Tabib A, Leroux C, Mornex JF, Loire R: Accelerated coronary atherosclerosis and arteriosclerosis in young human-immunodeficiency-virus- positive patients. Coron Artery Dis 11:41-16, 2000
48. Cushman M, Legault C, Barret-Connor E, Stefanick ML, Kessler C, Judd HL, Sakkinen PA, Tracy RP: Effect of postmenopausal hormones on inflammation- sensitive proteins. The postmenopausal estrogen/progestin interventions (PEPI) study. Circulation 100:717-722, 1999
49. Stenvinkel P, Wanner C, Metzger T, Heimbürger O, Mallamaci F, Tripepi G, Zocalli C: Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage? In press Kidney Int, 2002
50. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, Rose-John S, Fuller GM, Topley N, Jones SA: IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leucocyte recruitment seen during acute inflammation. Immunity 14:705-714, 2001
51. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V: Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148:209-214, 2000
52. Bologa RM, Levine DM, Parker TS, Cheigh JS, Seur D, Stenzel KH, Rubin AL: Inlerleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 32:107-114, 1998
53. Pecoits-Filho R, Barany B, Lindholm B, Heimbürger O, Stenvinkel P: Interleukin-6 is an independent predictor of mortality in patients starting peritoneal dialysis. Nephrol Dial Transpl 17:1684-1688, 2002
54. Stenvinkel P, Heimbürger O, Jogestrand T: Elevated interleukin-6 predicts progressive carotid atherosclerosis in dialysis patients: association to Chlamydia pneumoniae seropositivity. Am J Kidney Dis 39:274-282, 2002
55. Volpato S, Guralnik JM, Ferruci L, Balfour J, Chaves P, Fried LP, Harris TB: Cardiovascular disease, interleukin-6, and risk of mortality in older women: the womans health and aging study. Circulation 103:947-953, 2001
56. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WHJ, Heimovitz H, Cohen HJ, Wallace R: Association of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 106:506-512, 1999
57. Torzewski J, Torzewski M, Bowyer DE, Fröhlich M, Koenig W, Waltenberger J, Fitzsimmons C, Hombach V: C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Tromb Vasc Biol 18:1386-1392, 1998
58. Lagrand WK, Niessen HWM, Wolbink G-J, Jaspars LH, Visser CA, Verheugt FWA, Meijer CJLM, Hack E: C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 95:91-103, 1997
59. Pasceri V, Willerson JT, Yeh ET: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102:2165-2168, 2000
60. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M: Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL acainst LDL oxidation in aortic wall cell cocultures. J Clin Invest 96:2758-2767, 1995
61. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF: Lipoprotein (a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86:475-482, 1992
62. Smith EB, Thompson WD: Fibrin as a factor in atherogencsis. Thromb Res 73:1-19, 1994
63. Huber SA, Sakkinen P, Conze D, Hardin N, Tracy R: Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol 19:2364-2367, 1999
64. Pigott R, Dillon LP, Hemmingway IH, Gearing AJ: Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatant of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 187:584-589, 1992
65. Elhage R, Clamens S, Besnard S, Mallat Z, Tedgui A, Arnal J, Maret A, Bayard F: Involvement of interleukin-6 in atherosclerosis but not in the prevention of fatty streak formation by 17beta-estradiol in apolipoprotein E-deficient mice. Atherosclerosis 156:315-320, 2001
66. Zuckerman SH, O'Neal L: Endotoxin and GM.CSF-mediated down-regulation of macropnaee apo E secretion is inhibited by a TNF-specific monoclonal antibody. J Leukoc Biol 55:743-748, 1994
67. Tintut Y, Patel J, Parhami F, Demer LL: Tumor necrosis factor-α promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 102:2636-2642, 2000
68. Bhagat K, Vallance P: Inflammatory cytokines impair endolhelium-dependent dilatation in human veins in vivo. Circulation 96:3042-3047, 1997
69. Moller DE: Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 11:212-217, 2000
70. Smith DA, Irving SD, Sheldon J, Cole D, Kaski JC: Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation 104:746-749, 2001
71. Girndt M, Kaul H, Sester U, Ulrich C, Sester M, Georg T, Köhler H: Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. Kidney Int 62:949-955, 2002
72. DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J: Insulin resistance in uremia. J Clin Invest 67:563-568, 1981
73. Alvestrand A: Carbohydrate and insulin metabolism in renal failure. Kidney Int 52(suppl 62):S4S-S52, 1997
74. Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihs KL, Alleyne S, Cruz I, Yanovski JA, Veis J: Immunologic function and survival in hemodialysis patients. Kidney Int 54:236-244, 1998
75. Halse RO, Pearson SL, McCormack JG, Yeaman SJ, Taylor R: Effects of tumour necrosis factor-alpha on insulin action in cultured human muscle cells. Diabetes 50:1102-1109, 2001
76. Solomon SS, Usdan LS, Palazzolo MR: Mechanisms involved in tumor necrosis factor-alpha induction of insulin resistance and its reversal by thiazolidinedione(s). Am J Med Sci 322:75-78, 2001
77. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G: Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol 208:E745-E751, 2001
78. Togashi N, Ura N, Higashiura K, Murakami H, Shimamoto K: The contribution of skeletal muscle tumor necrosis factor-alpha to insulin resistance and hypertension in fructose-fed rats. J Hypertens 18:1605-1610, 2000
79. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB: Elevated C-reactive protein levels in overweight and obese adults. JAMA 282:2131-2135, 1999
80. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC: C-reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 312:1061-1065, 1996
81. Hak AE, Pols HA, Stehouwer CD, Meijer J, Kilian AJ, Hofman A, Breteler MM, Witteman JC: Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam study. J Clin Endocrinol Metab 86:4398-4405, 2001
82. Fernandez-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J, Ricart W: Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 86:1154-1159, 2001
83. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE: Outcome and risk factors for left ventricular disorders in chronic uremia. Nephrol Dial Transplant 11:1277-1285, 1996
84. Sato Y, Takatsu Y, Kataoka K, Yamada T, Taniguchi R, Sasayama S, Matsumori A: Serial circulating concentrations of C-rcactive protein, interleukin (IL)-4, and IL-6 in patients with acute left heart decompensation. Clin Cardiol 22:811-813, 1999
85. Schindler R, Dinarello CA, Koch KM: Angiotensin-convening enzyme inhibitors suppress synthesis of tumor necrosis factor and interleukin 1 by human peripheral blood mononuclear cells. Cytokine 7:526-533, 1995
86. Fukuzawa M, Satoh J, Sagara M, Muto G, Muto Y, Nishimura S, Miyagudri S, Qfang X, Sakata Y, Nakazawa T, Ikehata F, Ohta S, Toyota T: Angiotensin- converting enzyme inhibitors suppress production of tumor necrosis factor-alpha in vitro and in vivo. Immunopharmacology 36:49-55, 1997
87. Gullestad L, Aukrust P, Ueland T, Espevik T, Yee G, Vagelos R, Froland SS, Fowler M: Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol 34:2061-2067, 1999
88. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoti T, Kinashita M: Angiotensin II type 1 receptor antagonists decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol 35:714-721, 2000
89. Stenvinkel P, Andersson A, Wang T, Lindholm B, Bergström J, Palmblad J, Heimbürger O, Cederholm T: Do ACE-inhibitors suppress tumor necrosis factor-α production in advanced chronic renal failure? J Intern Med 246:503-507, 1999
90. Ikonomidis I, Andreotti F, Economou E, Stefanidis C, Toutouzas P, Nihoyannopoulos P: Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 100:793-798, 1999
91. Livio M, Benigni A, Vigano G, Mecca G, Remuzzi G: Moderate doses of aspirin and risk of bleeding in renal failure. Lancet 1:414-416, 1986
92. Ridker PM, Rifai N, Lowenthal SP: Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 103:1191-1193, 2001
93. Albert MA, Danielsson E, Rifai N, Ridker PM, Investigators P: Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/ CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286:64-70, 2001
94. Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB: Effects of simulation on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 39:1213-1217, 2002
95. Diomede L, Albani D, Sottocorno M, Donati MB, Bianchi M, Fruscella P, Saloma M: In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 21:1327-1332, 2001
96. Paolisso G, Barbagallo M, Petrella G, Ragno E, Barbieri M, Giordano M, Varricchio M: Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis 150:121-127, 2000
97. Seliger SI, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, Stehman-Breen CO: HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 61:297-304, 2002
98. Schindler R, Boenisch O, Fischer C, Frei U: Effect of the hemodialysis membrane on the inflammatory reaction in vivo. Clin Nephrol 53:452-459, 2000
99. Sitter T, Bergner A, Schiffl H: Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 15:1207-1211, 2000
100. Chung SH, Stenvinkel P, Bergstrom J, Lindholm B: Biocompatibility of new peritoneal dialysis solutions: what can we hope to achieve? Perit Dial Int 20(suppl 5):S57-S67, 2000
101. Kopple J, Bernard D, Messana J, Swartz R, Bergström J, Lindholm B, Lim V, Brunori G, Leiscrowitz M, Bier DM: Treatment of malnourished CAPD patients with an amino acid based dialysate. Kidney Int 47:1148-1157 1995
102. Witko-Sarsat V, Friedlander M, Khoa TN, Capeillére-Blandin C, Nguyen AT, Canteloup S, Dayer JM, Jungers P, Drüeke T, Descamps-Latscha B: Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161:2524-2532, 1998
103. Grimble RF: Nutritional modulation of cytokine biology. Nutrition 14:634-640, 1998
104. Devaraj S, Jialal I: Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type-2 diabetic patients. Free Radic Biol Med 29:790-792, 2000
105. Uppritchard JE, Sutherland WHF, Mann JI: Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes. Diabetes Care 23:733-738, 2000
106. Yoshikawa T, Yoshida N: Vitamin E and leucocyte-endothelial cell interactions. Antioxid Redox Signal 2:821-825, 2000
107. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS: Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 356:1213-1218, 2000
108. Satoh M, Yamasaki Y, Nagake Y, Kashara J, Hashimoto M, Nakaniski N, Makino H: Oxidative stress is reduced by the long-term use of vitamin E-coated dialysis filters. Kidney Int 59:1943-1950, 2001
109. Mune M, Yukawa S, Kishino M, Otani H, Kimura K, Nishikawa O, Takahashi T, Kodama N, Saika Y, Yamada Y: Effect of vitamin E on lipid metabolism and atherosclerosis in ESRD patients. Kidney Int 56(suppl 71):126-129, 1999
110. Omata M, Higuchi C, Demura R, Sanaka T, Nihei H: Reduction of neutrophil activation by vitamin E modified dialyzer membranes. Nephron 85:221-231, 2000